BioVie Inc. Files 8-K Report

TL;DR

BioVie Inc. filed a standard 8-K, no major news.

AI Summary

BioVie Inc. filed an 8-K on March 1, 2024, reporting other events and financial statements. The company, formerly known as NanoAntibiotics, Inc., is incorporated in Nevada and operates in the pharmaceutical preparations sector. The filing does not disclose specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This filing serves as a routine update for BioVie Inc. investors, confirming their status and reporting requirements are being met with the SEC.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not contain any new material information that would inherently increase risk.

Key Players & Entities

• BIOVIE INC. (company) — Registrant
• NANOANTIBIOTICS, INC. (company) — Former Company Name
• March 1, 2024 (date) — Date of Report
• Nevada (jurisdiction) — State of Incorporation
• 680 W Nye Lane Suite 201 Carson City, NV 89703 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — tered Class A Common Stock, par value $0.0001 per share BIVI The Nasdaq Stock Marke

Filing Documents

• bivi-20240301_8k.htm (8-K) — 27KB
• bivi-20240301_8kex99z1.htm (EX-99.1) — 22KB
• 0001520138-24-000079.txt ( ) — 228KB
• bivi-20240301.xsd (EX-101.SCH) — 3KB
• bivi-20240301_lab.xml (EX-101.LAB) — 33KB
• bivi-20240301_pre.xml (EX-101.PRE) — 22KB
• bivi-20240301_8k_htm.xml (XML) — 4KB

01

Item 8.01 Other Events. On March 1, 2024, BioVie Inc. (the "Company") issued a press release announcing the presentation of " Improvement of Non-Motor Symptoms with NE3107 Adjunctive to Carbidopa/Levodopa in Patients with Parkinson's Disease: A Phase 2A, Placebo-Controlled Study " and " Clinical Outcomes from a Phase 3, Randomized, Placebo-Controlled Trial of NE3107 in Subjects with Mild to Moderate Probable Alzheimer's Disease " at the International Conference on Alzheimer's and Parkinson's Diseases 2024 in Lisbon, Portugal. The Company is filing a copy of the press release, which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. In this report, forward-looking statements include, but are not limited to, the potential impact of NE3107 on cognition and function among study participants and topline data from the NE3107 trial. Although the Company believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to certain risks, including but are not limited to, the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair the Company's ability to pay future dividends, the Company's ability tocomplete the Company's pre-clinical or clinical studies and to obtain approval for the Company's productcandidates, the Company's ability to successfully defend potential future litigation, changes in local or national economic conditionsas well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the Securities and Exchange Commission, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. The Company does not undertake any duty to update any statements contained herein (including any forward-looking

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits . Exhibit No. Description 99.1 Press Release dated March 1, 2024. 104 Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 1, 2024 BIOVIE INC. By: /s/ Joanne Wendy Kim Name: Joanne Wendy Kim Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR